Tests elecoglipron alone or with dapagliflozin for type 2 diabetes
Tests elecoglipron, alone or with dapagliflozin, in adults with type 2 diabetes.
Plain-language title generated from the registry record
Registry title: A Phase III Study to Investigate the Efficacy and Safety of Elecoglipron Alone or in Combination With Dapagliflozin Compared With Placebo in Adults With Type 2 Diabetes Mellitus
Key facts
- Where
- Buenos Aires, CABA, Ciudad de Buenos Aires, Mar del Plata, San Nicolás, San Vicente, and Santa Fe, ArgentinaSee the 7 sites
- Phase
- Phase 3
Where in Argentina
- Buenos AiresBuenos Aires, ArgentinaNot yet recruiting
- CABACABA, ArgentinaNot yet recruiting
- Ciudad de Buenos AiresCiudad de Buenos Aires, ArgentinaNot yet recruiting
- Mar del PlataMar del Plata, ArgentinaNot yet recruiting
- San NicolásSan Nicolás, ArgentinaNot yet recruiting
- San VicenteSan Vicente, ArgentinaNot yet recruiting
- Santa FeSanta Fe, ArgentinaNot yet recruiting
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- AstraZeneca
- Trial code
- NCT07662044EU 2025-523936-37-00
- Record updated
- 31 August 2026
- Original description
The purpose of this study is to evaluate the efficacy, safety, and tolerability of elecoglipron alone or in combination with dapagliflozin compared with placebo in adults with type 2 diabetes mellitus (T2DM) inadequately managed with lifestyle management alone or treated with other background glucose-lowering medication.Read full original descriptionShow less
A Randomized, Double-blind, Parallel-group Phase III Study to Evaluate the Efficacy, Safety, and Tolerability of Elecoglipron Alone or in Combination With Dapagliflozin Compared With Placebo in Adults With Type 2 Diabetes Mellitus (Eluminate-1)
The purpose of this study is to evaluate the efficacy, safety, and tolerability of elecoglipron alone or in combination with dapagliflozin compared with placebo in adults with type 2 diabetes mellitus (T2DM) inadequately managed with lifestyle management alone or treated with other background glucose-lowering medication.
Inclusion: Diagnosed with Type 2 Diabetes Mellitus (T2DM) for at least 90 days prior to screening; T2DM inadequately managed with lifestyle management alone or on stable treatment with other background glucose-lowering medication; HbA1c value of ≥ 7% to ≤ 10.5% (53 to 91.3 mmol/mol); Body mass index (BMI) of ≥ 23 kg/m2 at screening; Stable body weight (self-reported or documented) for 90 days prior to screening.
Exclusion: Currently receiving or anticipated to receive, therapeutic intervention for diabetic retinopathy and/or macular edema; Have had more than one episode of severe hypoglycemia within 180 days prior to screening or has a history of hypoglycemia unawareness or poor recognition of hypoglycemic symptoms; Type 1 diabetes, secondary forms of diabetes (including congenital forms), or history of ketoacidosis or hyperosmolar coma; Clinically significant condition affecting the upper GI tract or chronic use of any medication that affects gastric motility or gastric emptying; History of acute or chronic pancreatitis; Severe congestive heart failure (New York Heart Association IV); History/family history of medullary thyroid cancer or multiple endocrine neoplasia type 2.